

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
)
 Mario Huesca) Art Unit: 1611
)
 Application No. 10/579,149) Examiner: Kortney L. Klinkel
)
 Filing Date: January 19, 2007) Confirmation No. 8922
)
 For: ARYL IMIDAZOLES AND THEIR USE)
 AS ANTI-CANCER AGENTS)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BALLARD SPAHR LLP
Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. § 1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

In accordance with the provisions of M.P.E.P. § 2001.06(b) and 37 C.F.R. § 1.98(b)(3), Applicants would like to bring to the attention of the Examiner the existence of the co-pending patent application(s) identified below, which were filed in the United States Patent and Trademark Office:

	<u>Application No.</u>	<u>Date Filed</u>	<u>Inventors</u>	<u>Attorney Docket No.</u>
1.	11/915,527*	November 21, 2007	Huesca et al.	0555186/0113866
2.	10/525,690*	October 24, 2006	Al-Qawasmeh et al.	16526US01

ATTORNEY DOCKET NO. 13198.0007U1
Application No. 10/579,149

The pending application(s) identified with an asterisk (*) are stored in the Image File Wrapper (IFW) system of the USPTO. Accordingly, copies of the cited specification(s), including the claims and drawings thereof, are not enclosed in accordance with the waiver to 37 CFR 1.98(a)(2)(iii) dated September 21, 2004.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(4), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants following the Request for Continued Examination under 37 C.F.R. § 1.114 filed concurrently herewith.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

BALLARD SPAHR ANDREWS &
INGERSOLL, LLP

/Christopher L. Curfman/

Christopher L. Curfman, JD, PhD
Registration No. 52,787

BALLARD SPAHR LLP
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

ATTORNEY DOCKET NO. 13198.0007U1
Application No. 10/579,149

CERTIFICATE OF EFS-WEB SUBMISSION UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being submitted electronically via EFS-WEB submission, on the date indicated below.

/Christopher L. Curfman/

November 6, 2009

Christopher L. Curfman, JD, PhD

Date